RogCon U.R.

RogCon U.R., a sister company of RogCon Biosciences, is focused on the research and development of novel, disease-modifying compounds that up-regulate SCN2A for the treatment of loss-of-function mutations in SCN2A causing autism and epilepsy. RogCon U.R. is working in partnership with a fellow biotechnology company, The Florey Institute and several others, on this platform. Stay tuned for more updates from RogCon U.R.

Indication Discovery Pre-Clinical Clinical
RCUR-313
RCUR-SMP